DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Asian-Americans face obesity-related disease at BMI 23+ (vs Western 30+). South Korean + Japanese guidelines allow GLP‑1 at BMI 25. How US thresholds miss AAPI patients + how to qualify.
BMI thresholds aren\'t one-size-fits-all
Asian populations develop T2D, NAFLD, and cardiovascular disease at lower BMIs than Western populations. WHO Asia-Pacific recommends overweight ≥23, obesity ≥27. Korean Society for the Study of Obesity 2023 + KFDA approve GLP-1 at BMI ≥25 with comorbidity. US labels haven\'t adapted — this page bridges the gap.
| Region/Population | Overweight | Obesity |
|---|---|---|
| US (FDA labeling) | ≥25 | ≥30 |
| South Korea (KFDA) | ≥23 | ≥25 |
| Japan (JASSO) | ≥23 | ≥25 |
| Singapore (HPB) | ≥23 | ≥27.5 |
| WHO Asia-Pacific (2004) | ≥23 | ≥27.5 |
US labels reflect 2014 FDA approval criteria. International evidence accumulated since suggests these thresholds undercount AAPI metabolic risk.
US FDA labeling requires BMI ≥27 with at least one comorbidity for GLP-1 weight-loss indication. Asian-Americans with BMI 25-29 often have multiple qualifying comorbidities at thresholds below Western screening levels. Discuss with prescriber:
Asian populations develop higher visceral fat at lower BMIs and have higher rates of T2D, NAFLD, and metabolic syndrome at BMI 23-27 ranges. WHO Asia-Pacific (2004) recommends BMI cutoffs: overweight ≥23, obesity ≥27 for Asian populations vs WHO general ≥25 / ≥30. Body composition matters more than BMI alone.
Yes — Korean Society for the Study of Obesity 2023 guidelines + KFDA approval pathway include GLP-1 at BMI ≥25 with comorbidity. Reflects accumulating evidence that Asian metabolic disease threshold sits at ~25, not 30. Singapore, Japan, Taiwan, Hong Kong have similar updated guidelines.
US labels require BMI ≥30 OR ≥27 with comorbidity. Asian-Americans at BMI 25-26 with elevated waist circumference + insulin resistance often qualify under the ≥27+comorbidity pathway. Document: T2D (or pre-diabetes), hypertension, dyslipidemia, NAFLD, or PCOS. Even one qualifies.
Yes if comorbidity is documented. Most US commercial plans use FDA labeling criteria (BMI ≥27 + comorbidity). Asian-American patients often have qualifying comorbidities at lower BMIs — ensure prescriber documents specific ICD-10 codes (E11.9 T2D, I10 HTN, K76.0 NAFLD, E78.5 dyslipidemia).
STEP 7 (semaglutide in East Asian patients) showed 12.1% weight loss at 44 weeks — comparable to Western populations. SURPASS-AP-Combo (tirzepatide in T2D, Asian-predominant) demonstrated similar A1C reduction. Treatment efficacy doesn't differ — only the BMI threshold for initiation does.
IDF criteria for Asian metabolic syndrome: waist ≥90cm men, ≥80cm women (vs Western ≥102 / ≥88). Discuss with prescriber — many use waist as primary obesity indicator for Asian patients, with BMI as supporting evidence.